Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

NEW YORK — Oxford BioDynamics reported on Wednesday a 24 percent drop in revenues for its fiscal year 2019 amid a decline in revenues generated in the US.

For the 12-month period ended Sept. 30, the UK-based company's revenues — which were generated entirely from epigenetic biomarker research and development alliances with commercial and academic partners — fell to £907,000 ($1.2 million) from £1.2 million in the same period last year. US revenues were down 69 percent to £126,000 from £405,000, while revenues generated in the rest of the world were flat at £781,000.

"Not only have we signed additional collaboration agreements [in 2019], but we have also seen EpiSwitch [biomarker technology] being used in high profile UK and US clinical trials," Oxford BioDynamics CEO Christian Hoyer Millar said in a statement. "We believe there is significant potential for EpiSwitch biomarkers to benefit a range of diseases, but we have been particularly pleased with the progress we have announced in [immuno-oncology.]"

Earlier this year, Oxford BioDynamics announced that its EpiSwitch test for prostate cancer will be evaluated in a nearly 300-patient study in the UK.

Oxford BioDynamics' fiscal 2019 net loss grew to £2.8 million, or £.03 per share, from £2.0 million, or £.02 per share, the year before.

R&D spending declined 32 percent to £468,000 from £693,000, while general and administrative costs grew 27 percent to £1.4 million from £1.1 million.

At the end of September, Oxford BioDynamics had cash and cash equivalents totaling £5.2 million.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.